home | news & events | pipeline | search | careers | contact us

Investors

Overview

Idera Pharmaceuticals applies its proprietary Toll-like Receptor (TLR) drug discovery platform to create immune modulatory drug candidates. The Company's TLR-targeted candidates are being developed to treat autoimmune and inflammatory diseases, cancer, and for use as vaccine adjuvants. Additionally, the Company is advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-associated genes.

... 
More >>
Recent NewsMore >>
DateTitle 
05/09/12Idera Pharmaceuticals Reports First Quarter 2012 Financial Results
CAMBRIDGE, Mass., May 09, 2012 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported financial results for the quarter ended March 31, 2012. "We are focusing our development effort on our autoimmune disease program and have continued to advance our lead candidates, IMO-3100 and IMO-8400. We initiated a Phase 2 study of IMO-3100 in patients with psoriasis in the second quarter and expect to complete it during the first half of 2013.... 
Printer Friendly Version
05/07/12Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis
IMO-8400 is a Lead Candidate for Development in Lupus CAMBRIDGE, Mass., May 07, 2012 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs). The data were presented at the American Asso... 
Printer Friendly Version
05/03/12Idera Pharmaceuticals Announces Top-line Results from a Phase 2 Clinical Trial of IMO-2055 in Treatment of Patients with Advanced Head and Neck Cancer
CAMBRIDGE, Mass., May 03, 2012 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced top-line results of a randomized, controlled Phase 2 clinical trial of IMO-2055, the Company's investigational oncology product candidate targeting Toll-like Receptor 9 in combination with Erbitux(R) (cetuximab) for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in patients who previously progressed on c... 
Printer Friendly Version
05/01/12Idera Pharmaceuticals Announces Presentation of Preclinical Data of IMO-8400 in Both Lupus and Psoriasis Models
Data to Be Presented at American Association of Immunologists Meeting 2012 CAMBRIDGE, Mass., May 01, 2012 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications. The data fro... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2011 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.